State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Oncoimmunology. 2021 Jun 21;10(1):1938476. doi: 10.1080/2162402X.2021.1938476.
Circulating tumor cells (CTCs) are considered to be related to the prognosis of cancer patients. CTC is a powerful indicator for recurrence or metastasis. The relationship, however, between the expression of programmed cell death receptor ligand 1 (PD-L1) on CTCs in peripheral blood and the prognosis, is still controversial. Here, we conducted a meta-analysis to evaluate its prognostic value. A total of 20 articles were screened from PubMed, Embase, Cochrane, China National Knowledge Internet (CNKI) and WanFang Database, and the Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined to study the relationship between PD-L1 expression on CTCs and prognosis. The expression of PD-L1 on CTCs in the peripheral blood of cancer patients is associated with poor prognosis. The pooled HRs for overall survival (OS) in cancer patients were 1.85 (95% CI, 1.29-2.66, = .001). The pooled HRs for progression-free survival (PFS) in cancer patients were 1.50 (95% CI, 1.12-2.01; = .007). This is the first meta-analysis to clarify the expression of PD-L1 on CTCs at baseline affects the prognosis of cancer patients. Patients with CTCs expressing PD-L1 had a shorter survival time than patients with CTCs not expressing PD-L1.
循环肿瘤细胞 (CTCs) 被认为与癌症患者的预后有关。CTC 是复发或转移的强有力指标。然而，外周血中 CTC 上程序性死亡受体配体 1 (PD-L1) 的表达与预后之间的关系仍存在争议。在这里，我们进行了一项荟萃分析来评估其预后价值。从 PubMed、Embase、Cochrane、中国国家知识基础设施 (CNKI) 和万方数据库中筛选出 20 篇文章，并对每个文章的风险比 (HR) 及其 95%置信区间 (CI) 进行合并，以研究 CTC 上 PD-L1 表达与预后之间的关系。癌症患者外周血中 CTCs 上 PD-L1 的表达与预后不良相关。癌症患者总生存期 (OS) 的合并 HR 为 1.85 (95% CI，1.29-2.66， =.001)。癌症患者无进展生存期 (PFS) 的合并 HR 为 1.50 (95% CI，1.12-2.01; =.007)。这是第一个阐明基线时 CTCs 上 PD-L1 的表达影响癌症患者预后的荟萃分析。表达 PD-L1 的 CTCs 的患者比不表达 PD-L1 的 CTCs 的患者的生存时间更短。
